机译:冠心病风险增加的女性中使用雷洛昔芬治疗的浸润性乳腺癌的发病率降低
Affiliations of authors: University of California, San Francisco, and the San Francisco VA Medical Center, San Francisco, CA (DG);
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (JAC);
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN (MJG, JS, JM);
Department of Epidemiology and Health Promotion, School of Public Health, Brussels Free University (ULB), Brussels, Belgium (MK);
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY (LM);
Department of Cardiac Medicine, Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London, London, UK (PC);
Emory University School of Medicine, Atlanta, GA (NKW);
Department of Family and Preventive Medicine, and Medicine, University of California, San Diego, La Jolla, CA (EBC);
机译:冠心病风险增加的女性中使用雷洛昔芬降低浸润性乳腺癌的发生率。
机译:在有乳腺癌和骨质疏松症风险的女性中管理浸润性乳腺癌的风险:雷洛昔芬的作用
机译:雷洛昔芬的最新进展:在降低绝经后女性浸润性乳腺癌风险中的作用
机译:乳腺癌 - 环境疾病?全世界乳腺癌发病率增加:一种调查生物合理性疾病风险因素的系统方法
机译:绝经前非洲裔美国妇女中的BMI升高与发生ER阴性乳腺癌的风险增加相关
机译:冠心病风险增加的女性中使用雷洛昔芬治疗的浸润性乳腺癌的发病率降低
机译:冠军风险增加的女性中泌乳乳腺癌的发生率降低